Sorrento Therapeutics Analyst Says Coronavirus Antibody Cocktail One Of Few Non-Vaccine Options
Sorrento Therapeutics Inc (NASDAQ: SRNE) shares spiked 158% Friday after the company disclosed that it has identified an antibody that demonstrated 100% inhibition of SARS-CoV-2 virus infection.
The Sorrento Analyst
H.C. Wainwright analyst Raghuram Selvaraju has a Buy rating on Sorrento with a $24 price target.
Comment: Every placement these guys do seems to sour. Time for an investigation?
Competing Comment: Every placement is subject to naked short selling pressure, without an investigation you cannot know for sure. Some companies do have histories. HCWainwreight appears to be one of them.
Sorrento Therapeutics Rips Higher, Coronavirus Antibody Shows 100% Inhibition In Experiment
Comment: Company had great news do they need 120% to get WALL ST to stop attacking the stock? Complete FRAUD Naked short in this name is HUNDREDS of MILLIONS of shares sold like 500 MILLION at $6 avg price is about $3 BILLION in 5 days COUNTERFEITED in 1 name